Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1233-1240

  De Brito, Luis R ^a   Batey, Mike A ^a   Zhao, Yan ^a   Squires, Matt S ^b   Maitland, Helen ^a   Leung, Hing Y ^a   Hall, Andrew G ^a   Jackson, Graham ^a   Newell, David R ^a   Irving, Julie A E ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

FGFR3; Multiple myeloma; PD173074; Sunitinib; Vandetanib; Vatalanib

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; HYBRID PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB; ZNF 198 FGFR1 FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; IC 50; IMMUNOBLOTTING; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPLE MYELOMA; PHTHALAZINES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051470769     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.011     Document Type: Article

References (39)

1. Seidl S., Kaufmann H., Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003, 4:557-564.
2. Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2:175-187.
3. Morgan G.J., Davies F.E., Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002, 56:223-234.
4. Vescio R.A., Cao J., Hong C.H., Lee J.C., Wu C.H., Der Danielian M., et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol 1995, 155:2487-2497.
5. Gado K., Domjan G., Kormos L., Falus A. Functional significance of genetic abnormalities in multiple myeloma. Haematologia (Budap) 2002, 32:191-208.
6. Malgeri U., Baldini L., Perfetti V., Fabris S., Vignarelli M.C., Colombo G., et al. Detection of t(4;14)(p16. 3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res 2000, 60:4058-4061.
7. Chesi M., Nardini E., Lim R.S., Smith K.D., Kuehl W.M., Bergsagel P.L. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998, 92:3025-3034.
8. Chang H., Qi X.Y., Samiee S., Yi Q.L., Chen C., Trudel S., et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005, 36:793-796.
9. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149.
10. Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001, 97:729-736.
11. Quintero-Rivera F., El-Sabbagh Badr R., Rao P.N. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma. Cancer Genet Cytogenet 2009, 195:92-93.
12. Li Z., Zhu Y.X., Plowright E.E., Bergsagel P.L., Chesi M., Patterson B., et al. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001, 97:2413-2419.
13. Plowright E.E., Li Z., Bergsagel P.L., Chesi M., Barber D.L., Branch D.R., et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000, 95:992-998.
14. Pollett J.B., Trudel S., Stern D., Li Z.H., Stewart A.K. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood 2002, 100:3819-3821.
15. Qing J., Du X., Chen Y., Chan P., Li H., Wu P., et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009, 119:1216-1229.
16. Trudel S., Stewart A.K., Rom E., Wei E., Li Z.H., Kotzer S., et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006, 107:4039-4046.
17. Chen J., Lee B.H., Williams I.R., Kutok J.L., Mitsiades C.S., Duclos N., et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005, 24:8259-8267.
18. Grand E.K., Chase A.J., Heath C., Rahemtulla A., Cross N.C. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004, 18:962-966.
19. Trudel S., Ely S., Farooqi Y., Affer M., Robbiani D.F., Chesi M., et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004, 103:3521-3528.
20. Trudel S., Li Z.H., Wei E., Wiesmann M., Chang H., Chen C., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005, 105:2941-2948.
21. Bisping G., Kropff M., Wenning D., Dreyer B., Bessonov S., Hilberg F., et al. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. Blood 2006, 107:2079-2089.
22. Xin X., Abrams T.J., Hollenbach P.W., Rendahl K.G., Tang Y., Oei Y.A., et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 2006, 12:4908-4915.
23. Mohammadi M., Froum S., Hamby J.M., Schroeder M.C., Panek R.L., Lu G.H., et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998, 17:5896-5904.
24. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003, 20:757-766.
25. Fabian M.A., Biggs W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329-336.
26. Smedley D., Demiroglu A., Abdul-Rauf M., Heath C., Cooper C., Shipley J., et al. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia 1999, 1:349-355.
27. Chang H., Stewart A.K., Qi X.Y., Li Z.H., Yi Q.L., Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005, 106:353-355.
28. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
29. Paterson J.L., Li Z., Wen X.Y., Masih-Khan E., Chang H., Pollett J.B., et al. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 2004, 124:595-603.
30. Onwuazor O.N., Wen X.Y., Wang D.Y., Zhuang L., Masih-Khan E., Claudio J., et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 2003, 102:772-773.
31. Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T., et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol 2001, 114:362-364.
32. Intini D., Baldini L., Lombardi L., Neri A. A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14). Leukemia 2002, 16:1201-1202.
33. Bisping G., Wenning D., Kropff M., Gustavus D., Muller-Tidow C., Stelljes M., et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin Cancer Res 2009, 15:520-531.
34. Vatsveen T.K., Brenne A.T., Dai H.Y., Waage A., Sundan A., Borset M. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). Eur J Haematol 2009, 83:471-476.
35. Ronchetti D., Greco A., Compasso S., Colombo G., Dell'Era P., Otsuki T., et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001, 20:3553-3562.
36. Zhu L., Somlo G., Zhou B., Shao J., Bedell V., Slovak M.L., et al. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 2005, 4:787-798.
37. Cho J.Y., Guo C., Torello M., Lunstrum G.P., Iwata T., Deng C., et al. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci U S A 2004, 101:609-614.
38. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
39. Matthews K. Use of SU11248 to inhibit proangiogenic growth factors in renal-cell carcinoma patients. Nat Clin Pract Oncol 2006, 3:119.